HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.
Last updated: 2026-11-21 19:24:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cognition Therapeutics, Inc. (CGTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.59, with a market capitalization of $57.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.55 to $1.81. This page covers its latest market performance, valuation, price trends and company information.
$57.12M | |
$0.60 | |
$0.62 | |
$0.56 | |
$0.60 | |
646.39K | |
469.74K | |
-- | |
$1.81 | |
$0.55 | |
-- | |
2026-09-30 |
Cognition Therapeutics, Inc. (CGTX) last closed at $0.59 as of 2026-11-21 00:52:00, down 1.76% ($0.01) from the previous close of $0.60.
During the latest regular trading session, CGTX traded between $0.56 and $0.62, with a volume of 646.39K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Cognition Therapeutics, Inc. (CGTX) moved from $0.68 to $0.59, representing a decline of 12.91% ($0.09).
The stock traded between $0.56 and $0.70 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 417.24 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.1%
CGTX is currently trading at $0.59, placing it 3.1% of the way from its 52-week low of $0.55 to its 52-week high of $1.81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Cognition Therapeutics, Inc. and CGTX stock.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.
Cognition Therapeutics announced findings from its Phase 2 START study showing that plasma p-tau217 blood testing can improve clinical trial screening efficiency by reducing the need for costly PET imaging. The approach may decrease burden on participants and trial sites while maintaining biomarker eligibility assessment. Enrollment in the START study was completed in Q4 2025, with top-line results expected after participants complete 18 months of treatment.
Eligible investors can buy real shares of Cognition Therapeutics, Inc. (CGTX) through MEXC Stocks. Follow these three steps to open a Stocks account, transfer USDT, and place a Stocks order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CGTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CGTX shares and USD.
CGTX Shares to USD
1.00 CGTX shares = 0.589 USD
Calculations are estimates based on the latest available price and are for reference only.